Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Lymphoma, Non-Hodgkin 3Carcinoma, Non-Small-Cell Lung 3Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Leukemia, Hairy Cell 2Xanthogranuloma, Juvenile 1Wilms Tumor 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Pancreatic Neoplasms 1Osteosarcoma 1Noonan syndrome 3 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Medulloblastoma 1Histiocytosis, Langerhans-Cell 1Histiocytic Sarcoma 1Hepatoblastoma 1Glioma 1Genomic Instability 1Ependymoma 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1

Interventions

Rituximab 5Specimen Handling 3Biopsy 3ibrutinib 2binimetinib 2Vemurafenib 2Cyclophosphamide 2Cladribine 2venetoclax 1tovorafenib 1polatuzumab vedotin 1pembrolizumab 1obinutuzumab 1immunotoxin HA22 1fludarabine phosphate 1fludarabine 1encorafenib 1acalabrutinib 1Whole-Body Irradiation 1Transplantation 1Tacrolimus 1Spinal Puncture 1Radiotherapy 1Prednisone 1Peripheral Blood Stem Cell Transplantation 1Mycophenolic Acid 1Magnetic Resonance Spectroscopy 1Lenalidomide 1High-Energy Shock Waves 1Famotidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia, Hairy Cell × Vemurafenib × 90 days × Clear all
NCT06561360 2026-05-26

A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
86 enrolled
Other hematologic neoplasm

Leukemia, Hairy Cell

NCT05388123 2026-04-24

Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia

Scripps Health

Phase 2 Completed
15 enrolled
Other hematologic neoplasm

Leukemia, Hairy Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡